Al Kamzari KAM & Constantinou C. Navigating the colorectal cancer maze: unveiling pathways to diagnosis, management, pathophysiology and prevention. Curr. Oncol. Rep. 2025 https://doi.org/10.1007/s11912-025-01707-w.
Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin Cancer Res. 2012;18:5537–45.
Google Scholar
Pang B, Wu H. Metabolic reprogramming in colorectal cancer: a review of aerobic glycolysis and its therapeutic implications for targeted treatment strategies. Cell Death Discov. 2025;11:321.
Google Scholar
Qiu X, Wang A, Wang J, Zhang Z, Tao L. Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions. Cell Death Discov. 2025;11:375.
Google Scholar
Chao KSC, Chang HY, Huang WC, Yuan TT, Chen WTL, Ke TW, et al. Tilting immunometabolic balance of tumor microenvironment by targeting ENO1 in KRAS-mutated colorectal and pancreatic cancers. Int J Radiat Oncol, Biol, Phys. 2024;120:S97.
Google Scholar
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036–46.
Google Scholar
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115–26.
Google Scholar
Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nat Rev Mol Cell Biol. 2022;23:141–61.
Google Scholar
Berner MJ, Wall SW, Echeverria GV. Deregulation of mitochondrial gene expression in cancer: mechanisms and therapeutic opportunities. Br J Cancer. 2024;131:1415–24.
Google Scholar
Tan BG, Gustafsson CM, Falkenberg M. Mechanisms and regulation of human mitochondrial transcription. Nat Rev Mol Cell Biol. 2024;25:119–32.
Google Scholar
Yan W, Xie C, Sun S, Zheng Q, Wang J, Wang Z, et al. SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression. EMBO J. 2024;43:2337–67.
Google Scholar
Wang R, Chen B, Pan Y, Wang M, Xiao Y, Shi D, et al. POLRMT enhances lenvatinib resistance in hepatocellular carcinoma cells by maintaining mitochondrial ATP production. Life Sci. 2025;379:123876.
Google Scholar
Wang H, Liu Y, Lu XS, Wu Y, Gu W, Yin G. Targeting POLRMT by IMT1 inhibits colorectal cancer cell growth. Cell Death Dis. 2024;15:643.
Google Scholar
Li SP, Ou L, Zhang Y, Shen FR, Chen YG. A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth. Cell Death Dis. 2023;14:152.
Google Scholar
Bonekamp NA, Peter B, Hillen HS, Felser A, Bergbrede T, Choidas A, et al. Small-molecule inhibitors of human mitochondrial DNA transcription. Nature. 2020;588:712–6.
Google Scholar
Li X, Ze X, Zhou S, Hu Z, He C, Jia Y, et al. Discovery of a novel, potent, orally active, and safe inhibitor targeting human mitochondrial RNA polymerase. J Med Chem. 2023;66:5118–53.
Google Scholar
Schatton D, Rugarli EI. Post-transcriptional regulation of mitochondrial function. Curr Opin Physiol. 2018;3:6–15.
Google Scholar
Reynaud K, Brothers M, Ly M, Ingolia NT. Dynamic post-transcriptional regulation by Mrn1 links cell wall homeostasis to mitochondrial structure and function. PLoS Genet. 2021;17:e1009521.
Google Scholar
Chujo T, Ohira T, Sakaguchi Y, Goshima N, Nomura N, Nagao A, et al. LRPPRC/SLIRP suppresses PNPase-mediated mRNA decay and promotes polyadenylation in human mitochondria. Nucleic Acids Res. 2012;40:8033–47.
Google Scholar
Singh V, Moran JC, Itoh Y, Soto IC, Fontanesi F, Couvillion M, et al. Structural basis of LRPPRC-SLIRP-dependent translation by the mitoribosome. Nat Struct Mol Biol. 2024;31:1838–47.
Google Scholar
Spahr H, Rozanska A, Li X, Atanassov I, Lightowlers RN, Chrzanowska-Lightowlers ZM, et al. SLIRP stabilizes LRPPRC via an RRM-PPR protein interface. Nucleic Acids Res. 2016;44:6868–82.
Google Scholar
Lagouge M, Mourier A, Lee HJ, Spahr H, Wai T, Kukat C, et al. SLIRP regulates the rate of mitochondrial protein synthesis and protects LRPPRC from degradation. PLoS Genet. 2015;11:e1005423.
Google Scholar
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556–60.
Google Scholar
Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675–8.
Google Scholar
Lin A, Yang H, Shi Y, Cheng Q, Liu Z, Zhang J, et al. PanCanSurvPlot: a large-scale pan-cancer survival analysis web application. BioRxiv 2022 https://doi.org/10.1101/2022.12.25.521884.
Wang J, Song X, Wei M, Qin L, Zhu Q, Wang S, et al. PCAS: an integrated tool for multi-dimensional cancer research utilizing clinical proteomic tumor analysis consortium data. Int J Mol Sci 2024;25.
Zhang J, Zhang Q. Using Seahorse machine to measure OCR and ECAR in cancer cells. Methods Mol Biol. 2019;1928:353–63.
Google Scholar
Caines JK, Barnes DA, Berry MD. The use of seahorse XF assays to interrogate real-time energy metabolism in cancer cell lines. Methods Mol Biol. 2022;2508:225–34.
Google Scholar
Gou Q, Gao L, Nie X, Pu W, Zhu J, Wang Y, et al. Long noncoding RNA AB074169 inhibits cell proliferation via modulation of KHSRP-mediated CDKN1a expression in papillary thyroid carcinoma. Cancer Res. 2018;78:4163–74.
Google Scholar
Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24:2482–90.
Google Scholar
Bonnay F, Veloso A, Steinmann V, Kocher T, Abdusselamoglu MD, Bajaj S, et al. Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis. Cell. 2020;182:1490–507.e1419.
Google Scholar
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14:4221.
Google Scholar
Li K, Guo J, Ming Y, Chen S, Zhang T, Ma H, et al. A circular RNA activated by TGFbeta promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability. Nat Commun. 2023;14:6876.
Google Scholar
Chen S, Li K, Guo J, Chen HN, Ming Y, Jin Y, et al. circNEIL3 inhibits tumor metastasis through recruiting the E3 ubiquitin ligase Nedd4L to degrade YBX1. Proc Natl Acad Sci USA. 2023;120:e2215132120.
Google Scholar
Guo J, Li K, Ming Y, Pan Y, Tan S, Ma H, et al. A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proc Natl Acad Sci USA. 2025;122:e2504320122.
Google Scholar
Sasarman F, Brunel-Guitton C, Antonicka H, Wai T, Shoubridge EA, Consortium L. LRPPRC and SLIRP interact in a ribonucleoprotein complex that regulates posttranscriptional gene expression in mitochondria. Mol Biol Cell. 2010;21:1315–23.
Google Scholar
Yang M, Lin W, Huang J, Mannucci A, Luo H. Novel immunotherapeutic approaches in gastric cancer. Precis Clin Med. 2024;7:pbae020.
Google Scholar
Pang H, Chen X, Yan M, Sun H. Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer. Precis Clin Med. 2025;8:pbae033.
Google Scholar
Tzeng SF, Yu YR, Park J, von Renesse J, Hsiao HW, Hsu CH, et al. PLT012, a humanized CD36-blocking antibody, is effective for unleashing antitumor immunity against liver cancer and liver metastasis. Cancer Discov. 2025;15:1676–96.
Google Scholar
Veiga SR, Ge X, Mercer CA, Hernandez-Alvarez MI, Thomas HE, Hernandez-Losa J, et al. Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR. Clin Cancer Res. 2018;24:3767–80.
Google Scholar
Schockel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab. 2015;3:11.
Google Scholar
Bendell JC, Patel MR, Infante JR, Kurkjian CD, Jones SF, Pant S, et al. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015;121:1056–63.
Google Scholar
Boland PM, Lenz HJ, Ciombor KK, Florou V, Pishvaian MJ, Cusnir M, et al. A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Invest N Drugs. 2025;43:60–8.
Google Scholar
Daglish SCD, Fennell EMJ & Graves LM. Targeting mitochondrial DNA transcription by POLRMT inhibition or depletion as a potential strategy for cancer treatment. Biomedicines 2023;11.
Li X, Liu L, Feng D, Shi Y, Huang L, Yu M, et al. Design, optimization, and biological evaluation of a novel quinoline-based POLRMT inhibitor for prostate cancer therapy. J Med Chem 2025 https://doi.org/10.1021/acs.jmedchem.5c00130.
Mennuni M, Filograna R, Felser A, Bonekamp NA, Giavalisco P, Lytovchenko O, et al. Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR-Cas9 screen. EMBO Rep. 2022;23:e53054.
Google Scholar
Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, et al. Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene. 2006;25:3065–70.
Google Scholar
Pham TCP, Raun SH, Havula E, Henriquez-Olguin C, Rubalcava-Gracia D, Frank E, et al. The mitochondrial mRNA-stabilizing protein SLIRP regulates skeletal muscle mitochondrial structure and respiration by exercise-recoverable mechanisms. Nat Commun. 2024;15:9826.
Google Scholar
Fernando CD, Jayasekara WSN, Inampudi C, Kohonen-Corish MRJ, Cooper WA, Beilharz TH, et al. A STAT3 protein complex required for mitochondrial mRNA stability and cancer. Cell Rep. 2023;42:113033.
Google Scholar
Bayona-Bafaluy MP, Sanchez-Cabo F, Fernandez-Silva P, Perez-Martos A, Enriquez JA. A genome-wide shRNA screen for new OxPhos-related genes. Mitochondrion. 2011;11:467–75.
Google Scholar
Jourdain AA, Koppen M, Wydro M, Rodley CD, Lightowlers RN, Chrzanowska-Lightowlers ZM, et al. GRSF1 regulates RNA processing in mitochondrial RNA granules. Cell Metab. 2013;17:399–410.
Google Scholar
Zhang X, Fryknas M, Hernlund E, Fayad W, De Milito A, Olofsson MH, et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014;5:3295.
Google Scholar
Vitiello GA, Medina BD, Zeng S, Bowler TG, Zhang JQ, Loo JK, et al. Mitochondrial inhibition augments the efficacy of Imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor. Clin Cancer Res. 2018;24:972–84.
Google Scholar
Baughman JM, Nilsson R, Gohil VM, Arlow DH, Gauhar Z, Mootha VK. A computational screen for regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis. PLoS Genet. 2009;5:e1000590.
Google Scholar
Hatchell EC, Colley SM, Beveridge DJ, Epis MR, Stuart LM, Giles KM, et al. SLIRP, a small SRA-binding protein, is a nuclear receptor corepressor. Mol Cell. 2006;22:657–68.
Google Scholar
Li L, Miao W, Williams P, Guo C, Wang Y. SLIRP interacts with helicases to facilitate 2’-O-methylation of rRNA and to promote translation. J Am Chem Soc. 2019;141:10958–61.
Google Scholar
Qi Z, Xue S, Chen J, Zhao W, Johnson K, Wen X, et al. Genome-wide mapping of RNA-protein associations through sequencing. Nat Biotechnol 2025 https://doi.org/10.1038/s41587-025-02780-z.
